Ted Lidie is the founder of Alien Labs, one of the most respected top-shelf cultivators in California. Ted built the business from the ground up and they were acquired by Connected in early 2017. Alien Labs remains a brand within the Connected family and they are sold in California, Arizona, and Florida.
I was excited to talk to Ted about how he grew Alien Labs, the origins of the Connected relationship, and learn more about the partnership with Trulieve that has allowed them to expand outside of California. We also dug into the traits of top-shelf flower, the benefits of solventless extraction, and the potential for Connected to enter the New York market. If you care about the cannabis part of cannabis investing, I think you will appreciate this episode.
To listen, you can click the link here or the tweet below. Twitter Spaces will play on any mobile device or on the desktop via a browser. They are like a podcast but hosted on Twitter.
The information in our newsletter may become outdated and we have no obligation to update it. The information in our newsletter is not intended to constitute individual investment advice and is not designed to meet your personal financial situation. It is provided for information purposes only and nothing herein constitutes investment, legal, accounting, or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor or a group of investors. It should not be assumed that any investments in securities, companies, sectors, or markets identified and described were or will be profitable. We strongly advise you to discuss your investment options with your financial adviser prior to making any investments, including whether any investment is suitable for your specific needs.
The information provided in our newsletter is private, privileged, and confidential information, licensed for your sole individual use as a subscriber. Green Giants reserves all rights to the content of this newsletter. Forwarding, copying, disseminating, or distributing this newsletter in whole or in part, including substantial quotation of any portion of the publication or any release of specific investment recommendations, is strictly prohibited.